Interference with Androgen Receptor and Its Ligands

$196,510P01FY2013CANIH

Univ Of North Carolina Chapel Hill, Chapel Hill NC

Investigators

Linked publications, trials & patents

Paper 30775248 Paper 30742064 Paper 29574604 Paper 29194687 Paper 28415728 Paper 28042025 Paper 27966447 Paper 27720894 Paper 27587619 Paper 26889756 Paper 26350767 Paper 26330556 Paper 25736582 Paper 25563353 Paper 25336698 Paper 25306183 Paper 24859441 Paper 24847527 Paper 24771515 Paper 24369139 Paper 24150795 Paper 24103312 Paper 23853093 Paper 23839233 Paper 23813737 Paper 23813697 Paper 23565755 Paper 23548616 Paper 23172223 Paper 23072969 Paper 22891251 Paper 22589544 Paper 22334658 Paper 22303438 Paper 22272301 Paper 21796524 Paper 21796519 Paper 21730049 Paper 21705451 Paper 21664945 Paper 21557268 Paper 21456342 Paper 21456341 Paper 21446007 Paper 21303972 Paper 21041310 Paper 21036700 Paper 20699437 Paper 20560527 Paper 20448036 Paper 20404538 Paper 19996220 Paper 19828458 Paper 19372581 Paper 19275204 Paper 19270533 Paper 19204997 Paper 19091347 Paper 19058139 Paper 18628304 Paper 18519676 Paper 18511414 Paper 18471792 Paper 18292195 Paper 18212060 Paper 18030362 Paper 17909037 Paper 17591767 Paper 17494760 Paper 16705743 Paper 16288044 Paper 16061644 Paper 16000557 Paper 15958619 Paper 15888205 Paper 15833875 Paper 15755991 Paper 15525515 Paper 15491717 Paper 15457671 Paper 15162375 Paper 15162374 Paper 15126802 Paper 15107424 Paper 14996731 Paper 14760063 Paper 14713853 Paper 14662770 Paper 14532783 Paper 12970744 Paper 12886520 Paper 12631612 Paper 12616728 Paper 12381725 Paper 12050280 Paper 11987153 Paper 11956106 Paper 11801547 Paper 11786415 Paper 11719283

Abstract

Project 1 has contributed to two paradigm changing discoveries. First, the androgen receptor (AR) pathway appears critical to the growth of castration-recurrent prostate cancer (CaP) in spite of castrate levels of circulating testicular androgens. Second, castration-recurrent CaP produces high tissue levels of testosterone (T) and dihydrotestosterone (DHT), the preferred AR ligand. Intracrine-produced testicular androgens present a target for novel therapies. Further advances may result from applying novel treatments to CaP coincidental with androgen deprivation therapy (ADT) when CaP cell death is at a maximum and surviving cells are under greatest stress. The central hypothesis of the proposed studies is that CaP can be cured or remission extended by a coordinated attack upon intracrine androgen metabolism and AR coincidental with elimination of circulating testicular androgens (medical or surgical castration). In order to test this hypothesis and allow the formulation of an appropriate clinical trial in advanced CaP, the response to ADT will be assessed using preclinical models in the immediate post-castration period. In general, cell or tissue sampling will be conducted just prior to castration and 12h and 1, 2, 4, 8, 16 and 30d after

View original record on NIH RePORTER →